Article Per Year (5 Year)
p-Index From 2021 - 2026
3.701
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran Brawijaya Indonesian Journal of Cancer Chemoprevention Indonesian Journal of Tropical and Infectious Disease Majalah Kesehatan FKUB Jurnal Respirologi Indonesia Jurnal Respirasi (JR) Medica Hospitalia Jurnal Pengabdian Masyarakat dalam Kesehatan Respiratory Science Malang Respiratory Journal Jurnal Klinik dan Riset Kesehatan Indonesian Journal of Cancer
Setyawan, Ungky Agus
Department Of Pulmonology And Respiratory Medicine Faculty Of Medicine Universitas Brawijaya Malang
Biochemistry, Genetics & Molecular Biology Dentistry Earth & Planetary Sciences Education Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health Other

Published : 27 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Respiratory Science

 1 
One Year Survival of Wild-Type Adenocarcinoma Lung Cancer Patients Receiving Chemotherapy at dr. Saiful Anwar Hospital, Malang Ungky Agus Setyawan; Hendy Setyo Yudhanto; Aura Madarina
Respiratory Science Vol. 2 No. 3 (2022): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v2i3.47

Abstract

Background: Lung cancer is one of the most common malignancies that leads to mortality. In Indonesia, lung cancer ranks first in men and third in women. The most common histological type of lung cancer is adenocarcinoma. Adenocarcinoma lung cancer is divided into 2 types, namely EGFR mutations and no mutations (wild-type). Chemotherapy is the treatment of choice for advanced wild-type adenocarcinoma lung cancer. This study aimed to assess the one-year survival of wild-type adenocarcinoma lung cancer patients receiving chemotherapy. Method: This study used a cross-sectional study design.Data were taken from the medical records of cancer patients at Dr. Saiful Anwar Hospital Malang in 2018-2019. Data were processed and analyzed by chi-square test. Results: Of the 54 subjects, 24 patients received carboplatin/ pemetrexed (44.4%), 15 patients received carboplatin/paclitaxel (27.8%), 9 patients received carboplatin/gemcitabine (16.7%), 2 patients received pemetrexed (3.7%), and 4 patients received gemcitabine (7.4%). The chemotherapy drug regimen had no correlation with one-year survival (P=0.899). Conclusion: There wasno significant difference between one-year survival andchemotherapy drug regimens. This study required a larger sample to minimize bias.
Analysis of C-Reactive Protein, Neutrophil-to-Lymphocyte Ratio, PaO2/FiO2 Ratio on the Success of High Flow Nasal Cannula Usage in Hospitalized COVID-19 Patients Arina Aftritia Izzati; Ungky Agus Setyawan; Rezki Tantular
Respiratory Science Vol. 3 No. 3 (2023): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v3i3.85

Abstract

Background: Several studies had shown High Flow Nasal Cannula (HFNC) is effective in treating hypoxemic COVID-19 patients. The C-Reactive Protein and Neutrophil-to-Lymphocyte Ratio is an inflammatory marker that could predict the severity of COVID-19, where the P/F ratio infers oxygenation status. Since COVID-19-related ARDS is closely related to a hyper-inflammatory state and HFNC becomes widely utilized for hypoxemic patients, it has become important to discover reliable inflammatory biomarkers related to therapeutic HFNC success. This study aims to assess the factors that influence the success of HNFC therapy, in terms of demographic and laboratory profiles of CRP, NLR, and P/F ratio. Method: A retrospective, single-center cohort study was conducted in a tertiary care hospital in Malang, East Java from January to March 2022. Subjects of 31 PCR-confirmed, hospitalized COVID-19 patients who were treated with HFNC were included. Results: This study involved 2 groups comprised of 19 subjects with successful HFNC and 12 patients who failed. Significant demographic factors affecting successful HFNC were female gender (OR=1.46 95% CI=1.08-1.99; P=0.037) and occupation type (P=0.023). Whereas, biomarkers of CRP (8.90±6.8 mg/L vs 12.39±11.7 mg/L; P=0.656), NLR (7.24±4.66 vs 12.85±12.9; P=0.243) and P/F ratio (171.40±54 vs 148.00±40; P=0.219) were found to be non-significant between successful and failed HFNC cohorts, respectively. Conclusion: HFNC could provide a specific positive end-expiratory pressure in COVID-19 patients with contributing factors of successful HFNC being female and occupational type. However, CRP, NLR, and P/F did not contribute significantly to HFNC's success.
Correlation Between Changes in NLR Value and RECIST among Lung Cancer Patients at Saiful Anwar Malang Hospital Kristianto, Fransiskus; Setyawan, Ungky Agus; Erawati, Dini Rachma
Respiratory Science Vol. 5 No. 1 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v5i1.141

Abstract

Background: In practice, clinicians use Response Evaluation Criteria in Solid Tumors (RECIST) to decide the progressivity of lung tumors. Besides RECIST, there is an inflammatory marker called Neutrophil to Lymphocyte Ratio (NLR), which has prognostic value in cancer patients. Many previous studies have shown that NLR can predict the prognosis because inflammation in cancer patients is part of the tumor progressivity.  Therefore, the changes in NLR value have the potency to be one of the ways to decide the progressivity of tumors in lung cancer patients. Method: This cross-sectional study was conducted to see whether there is a correlation between RECIST and NLR in 95 lung cancer patients at Saiful Anwar Hospital whose data were taken from January 2022 to May 2023. The variable will be tested using the chi-square test to see the correlation and the logistic regression method to obtain the odds ratio. Results: There is a significant correlation between changes in NLR and RECIST with P=0.041.  Through Logistic Regression Analysis, the value of the odds ratio is 2.46 (CI 95%=1.03-5.94).  In the group with progressive RECIST, the average NLR value after therapy was higher than the average NLR value after therapy in the non-progressive group. Conclusion: This study concludes that changes in NLR value have the potency to help the determination process of lung cancer progressivity as RECIST does.
Co-Authors Aditya Sri Listyoko Aditya Sri Listyoko Agil Dananjaya Ana Rima Ana Rima Setijadi Andarini, Sita Andreas Infianto Arfiansyah, Mochammad Aris Arif Santoso Arif Santoso Arina Aftritia Izzati Arinto Yudi Ponco Arinto Yudi Ponco Wardoyo Arinto Yudi Ponco Wardoyo Aura Madarina Binharyanto, Adlan Pratama Binharyanto Caesar Ensang Timuda Chaerani Bahar Dewi, Dinda Ary Miranda Dini Rachma Erawati Djajalaksana, Susanthy Dwi Rosa Eka Agustina Elisna Syahruddin Erawati, Dini Rachma Ermayanti, Sabrina Ermayanti, Sabrina Fadhila, Audri Shabrina Fahmi, Kristia Falyani, Silvy Amalia Febriawati, Juwita Ferry Dwi Kurniawan Harun Al Rasyid Haryati Haryati Haryati Haryati Hendri Wiyono, Hendri Hendy Setyo Yudhanto Hendy Setyo Yudhanto Hidayat, Moulid Ida Ayu Jasminarti Iin Noor Chozin Infianto, Andreas Jasminarti, Ida Ayu Jimmy Akbar Karliasari, Liana Kevin Wahyudy Prasetyo Kristianto, Fransiskus Kurniawan, Ferry Dwi Laksmi Wulandari Listyoko, Aditya Sri Mafisah, Saidah Maria Kristiani Muhamad Yusuf Musthafa Nathaniel Aditya Ngakan Putu Parsama Putra Ngakan Putu Parsama Putra Noni Novisari Soeroso Noorhamdani AS Parsama Putra , Ngakan Putu Permana, Deden Permatasari, Adinda Pramitra Pratiwi, Suryanti Dwi Putra, Andika Chandra Putra, Ngakan Putu Parsama Raden Dicky Wirawan Listiandoko Rakhma, Sastia Ramadhan, Fitratul Rezki Tantular Rezki Tantular Rozi, Achmad Syamsufandi Rumaratu, Simon Petrus Hardiyanto Santosa, Andrew Santoso, Andintia Aisyah Simon Petrus Sita Andarini Sri Melati Munir Sri Melati Munir Susanthy Djajalaksana Susanthy Djajalaksana Tantular, Rezki Taufiq Abdullah, Taufiq Teguh Rahayu Sartono Teguh Wahyu Sardjono Timuda, Caesar Ensang Tjahyadi, Rizal Muldani Tri Wahju Astuti Tri Wahju Astuti, Tri Wahju Ulfah Kartikasari Wardhana, Koernia Kusuma Yenny Widowati Yokanan Yudhanto, Hendy Setyo Zaini, Jamal